The firm that calls itself the leading oncology company in Japan strengthened its position on Wednesday with the approval of its breast cancer drug in a new indication in the Asian country.
Chugai Pharmaceutical (TYO: 4519), which is majority-owned by Swiss pharma giant Roche (ROG: SIX), has obtained a supplemental approval from the Japanese Ministry of Health, Labor and Welfare for Perjeta (pertuzumab) for the indication of neoadjuvant and adjuvant therapy for HER2-positive early breast cancer.
Perjeta is currently approved in Japan for HER2-positive inoperable or recurrent breast cancer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze